Physician profile
Frederick S Jones
NPI 1023044013
$2,934.38
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $465 · 2021: $515 · 2022: $1,023.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $545.79 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $447.06 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $295.56 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $278.19 | 2019-2022 | |
| Akebia Therapeutics INC | $164.40 | 2019-2022 | |
| Horizon Therapeutics Plc | $163.10 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $140.30 | 2019-2022 | |
| Amicus Therapeutics, INC. | $121.90 | 2019 | |
| Vifor Pharma, INC. | $120.17 | 2019-2022 | |
| Amgen INC. | $98.24 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $89.84 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.47 | 2022 | |
| Mallinckrodt Hospital Products INC. | $66.54 | 2020-2022 | |
| Calliditas Therapeutics US INC. | $50.79 | 2022 | |
| Genzyme Corporation | $47.22 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $45.85 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $42.94 | 2022 | |
| Mallinckrodt Enterprises LLC | $29.85 | 2019 | |
| Alnylam Pharmaceuticals INC. | $25.85 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.82 | 2021 | |
| Ani Pharmaceuticals, INC. | $22.22 | 2022 | |
| Glaxosmithkline, LLC. | $18.06 | 2021 | |
| Shire North American Group INC | $13.76 | 2019 | |
| Nuwellis, INC. | $12.46 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.